Viveve Medical, Inc. designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable accessories. It markets its products through sales employees and distributors in the United States, the Asia Pacific, Europe, the Middle East, Latin America, and Canada. Viveve Medical, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VIVE
CUSIPN/A
Phone720-696-8100
Debt
Debt-to-Equity Ratio1.55
Current Ratio6.47
Quick Ratio6.00
Price-To-Earnings
Trailing P/E Ratio-1.81
Forward P/E Ratio-2.43
P/E GrowthN/A
Sales & Book Value
Annual Sales$15.29 million
Price / Sales7.79
Cash FlowN/A
Price / CashN/A
Book Value($0.13) per share
Price / Book-29.31
Profitability
EPS (Most Recent Fiscal Year)($2.11)
Net Income$-36,950,000.00
Net Margins-269.24%
Return on Equity-437.98%
Return on Assets-103.63%
Miscellaneous
Employees103
Outstanding Shares31,270,000
Viveve Medical (NASDAQ:VIVE) Frequently Asked Questions
What is Viveve Medical's stock symbol?
Viveve Medical trades on the NASDAQ under the ticker symbol "VIVE."
How were Viveve Medical's earnings last quarter?
Viveve Medical Inc (NASDAQ:VIVE) announced its quarterly earnings data on Thursday, May, 10th. The company reported ($0.49) EPS for the quarter, missing the Zacks' consensus estimate of ($0.44) by $0.05. The company had revenue of $3.70 million for the quarter, compared to analyst estimates of $4.68 million. Viveve Medical had a negative return on equity of 437.98% and a negative net margin of 269.24%. View Viveve Medical's Earnings History.
What price target have analysts set for VIVE?
7 equities research analysts have issued 1-year price targets for Viveve Medical's stock. Their forecasts range from $6.00 to $11.00. On average, they expect Viveve Medical's share price to reach $9.20 in the next year. View Analyst Ratings for Viveve Medical.
What are Wall Street analysts saying about Viveve Medical stock?
Here are some recent quotes from research analysts about Viveve Medical stock:
- 1. Mizuho analysts commented, "We expect the trends in utilization and pricing to continue in 2018. FDA Approval of IDE to Conduct VIVEVE2 Clinical Trial. The FDA approved Viveve’s IDE to conduct a sexual function study in the U.S. The study is expected to start in 2Q18 and will include approximately 250 patients across 25 clinical sites in the U.S. and Canada. The primary endpoint will measure the mean change from baseline in the total FSFI (Female Sexual Function Index) at 12 months. Data from the study is expected in 2H19. Cash Position and Upcoming Catalysts. Viveve’s current cash position stands at approximately $55.7 mil following a recent $35.0 mil equity offering in February." (3/20/2018)
- 2. Maxim Group analysts commented, "4Q17 revenue of $5.1M, up 108% y/y, was inline with the preannouncement." (3/16/2018)
Who are some of Viveve Medical's key competitors?
Some companies that are related to Viveve Medical include Rockwell Medical (RMTI), Vision Sciences (CGNT), BioLife Solutions (BLFS), Helius Medical Technologies (HSDT), Fonar (FONR), Second Sight Medical Products (EYES), Zynex Inc. common stock (ZYXI), Edap Tms (EDAP), Semler Scientific (SMLR), IRIDEX (IRIX), BioSig Technologies (BSGM), Soleno Therapeutics (SLNO), Stereotaxis (STXS), Digirad (DRAD) and Aradigm (ARDM).
Who are Viveve Medical's key executives?
Viveve Medical's management team includes the folowing people:
- Ms. Patricia K. Scheller, CEO & Chairperson (Age 58)
- Mr. James Gregory Atkinson, Chief Bus. Officer & Pres (Age 60)
- Mr. Scott C. Durbin, CFO & Sec. (Age 49)
- Mr. Martin Kerber, VP of Operations
- Mr. Jim B. Robbins, VP of Fin. & Admin. (Age 54)
When did Viveve Medical IPO?
(VIVE) raised $13 million in an IPO on Tuesday, June 14th 2016. The company issued 1,600,000 shares at $8.00 per share. Ladenburg Thalmann and Craig-Hallum Capital Group acted as the underwriters for the IPO and Maxim Group was co-manager.
Has Viveve Medical been receiving favorable news coverage?
News coverage about VIVE stock has trended somewhat positive on Monday, Accern reports. The research group identifies positive and negative news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Viveve Medical earned a news sentiment score of 0.20 on Accern's scale. They also assigned news coverage about the company an impact score of 46.10 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are Viveve Medical's major shareholders?
Viveve Medical's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include venBio Select Advisor LLC (4.90%), BlackRock Inc. (2.50%), Wexford Capital LP (2.23%), Acuta Capital Partners LLC (2.19%), ING Groep NV (1.38%) and Northern Trust Corp (0.81%). Company insiders that own Viveve Medical stock include James G Atkinson, Patricia Scheller and Scott Durbin. View Institutional Ownership Trends for Viveve Medical.
Which institutional investors are buying Viveve Medical stock?
VIVE stock was purchased by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Wexford Capital LP, Acuta Capital Partners LLC, ING Groep NV, Northern Trust Corp, BlackRock Inc. and Spark Investment Management LLC. Company insiders that have bought Viveve Medical stock in the last two years include James G Atkinson, Patricia Scheller and Scott Durbin. View Insider Buying and Selling for Viveve Medical.
How do I buy shares of Viveve Medical?
Shares of VIVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Viveve Medical's stock price today?
One share of VIVE stock can currently be purchased for approximately $3.81.
How big of a company is Viveve Medical?
Viveve Medical has a market capitalization of $119.76 million and generates $15.29 million in revenue each year. The company earns $-36,950,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Viveve Medical employs 103 workers across the globe.
How can I contact Viveve Medical?
Viveve Medical's mailing address is 345 INVERNESS DRIVE SOUTH BUILDING B SUITE 250, ENGLEWOOD CO, 80112. The company can be reached via phone at 720-696-8100 or via email at [email protected]
MarketBeat Community Rating for Viveve Medical (VIVE)
MarketBeat's community ratings are surveys of what our community members think about Viveve Medical and other stocks. Vote "Outperform" if you believe VIVE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VIVE will underperform the S&P 500 over the long term. You may vote once every thirty days.
